【英語タイトル】Hepatitis Diagnostic Tests Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
	・商品コード：IMARC23FE0018 ・発行会社（調査会社）：IMARC ・発行日：2023年2月1日 ・ページ数：105 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール ・調査対象地域：グローバル ・産業分野：医療

The global hepatitis diagnostic tests market size reached US$ 5.6 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 7.5 Billion by 2028, exhibiting a growth rate (CAGR) of 5.1% during 2023-2028.

Hepatitis represents a major global health threat that requires an urgent response. According to estimates, hepatitis causes 1.3 Million-1.5 Million deaths each year, a figure that is comparable to the deaths caused by tuberculosis and even higher than those caused by HIV. Moreover, while mortality from diseases such as HIV, tuberculosis, and malaria are now declining, mortality from hepatitis has been rising. According to estimates around 325-350 Million people across the globe are carriers of hepatitis B or C virus infections, which may remain asymptomatic for decades. Moreover, every year, around 1.75 Million people get infected by the hepatitis C virus infection. Unless these people receive timely testing and treatment, they are at risk of severe liver disease and even death. Diagnostic tests help in the early detection of hepatitis infections and increase the chances of survival of the patient by correct medication and treatment.

The global demand of hepatitis diagnostic tests is currently exhibiting strong growth. This market is currently being catalyzed by a number of factors such as the increasing burden of hepatitis across the globe, rising number of blood transfusions and donations, technological advancements and the advantages offered by PoC (Point of Care) test, and rising awareness levels. A major trend being witnessed in this market has been a shift from conventional testing methods to molecular diagnostics. This has resulted in an increased accuracy and reduced the total time required to get the results.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global hepatitis diagnostic tests market report, along with forecasts at the global and regional level from 2023-2028. Our report has categorized the market based on test type.

Breakup by Test Type:

Blood Tests
Imaging Test
Liver Biopsy

Based on the test type, the market has been segmented into blood tests, imaging test and liver biopsy. Blood tests currently represent the biggest application. Blood tests are further segmented into liver function test, immunoassays, and nucleic acid tests.

Breakup by Region:

North America
Asia Pacific
Europe
Middle East and Africa
Latin America

Region-wise, the market has been segmented into North America, Asia Pacific, Europe, Middle East and Africa and Latin America. Amongst these, North America is the biggest market, accounting for the majority of the global market.

Competitive Landscape:
The competitive landscape of the market has also been examined with some of the key players being Siemens AG, Abbott Laboratories, MedMira Inc, Qiagen GmbH, Beckman Coulter Inc (Danaher Corporation), F. Hoffmann- La Roche AG, Diasorin S.p.A, bioMeriuex SA, Hologic Inc., and Bio-Rad Laboratories Inc.

Key Questions Answered in This Report
1. What was the size of the global hepatitis diagnostic tests market in 2022?
2. What is the expected growth rate of the global hepatitis diagnostic tests market during 2023-2028?
3. What are the key factors driving the global hepatitis diagnostic tests market?
4. What has been the impact of COVID-19 on the global hepatitis diagnostic tests market?
5. What is the breakup of the global hepatitis diagnostic tests market based on the test type?
6. What are the key regions in the global hepatitis diagnostic tests market?
7. Who are the key players/companies in the global hepatitis diagnostic tests market?